Success Metrics

Clinical Success Rate

100.0%

Based on 12 completed trials

Completion Rate

100%(12/12)

Active Trials

0(0%)

Results Posted

100%(12 trials)

Phase Distribution

Ph phase_2

Ph phase_3

38%

Ph phase_1

54%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

7(53.8%)

Phase 2Efficacy & side effects

1(7.7%)

Phase 3Large-scale testing

5(38.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(12)

Terminated(1)

Detailed Status

Completed12

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 17 (53.8%)

Phase 21 (7.7%)

Phase 35 (38.5%)

Trials by Status

completed1292%

withdrawn18%

Recent Activity

0 active trials

Showing 5 of 13

completedphase_2

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

NCT03514641

completedphase_1

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT03514641Phase 2

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Completed

NCT03197324Phase 1

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Completed

NCT02956044Phase 1

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Completed

NCT02558296Phase 3

Bexagliflozin Efficacy and Safety Trial

Completed

NCT03296800Phase 1

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Completed

NCT02836873Phase 3

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Completed

NCT02715258Phase 3

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Completed

NCT03115112Phase 3

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed

NCT02820298Phase 1

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Completed

NCT03557658Phase 1

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

Completed

NCT03167411Phase 1

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Completed

NCT02769481Phase 3

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed

NCT03417076Phase 1

Absolute Bioavailability Study With Bexagliflozin

Withdrawn

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13